Blueprint Medicines — Corporate Update (June 2022)
6 slides from Blueprint Medicines's corporate update, Jun 30, 2022
Slide 1: Transformative Strategic Financing Collaboration With Sixth Street and Royalty Pharma
Transformative Strategic Financing Collaboration With Sixth Street and Royalty Pharma June 30, 2022 Cyndi N. Systemic mastocytosis patient © 2022 Blueprint Medicines Corporation
Slide 2: Blueprint Medicines call participants
Blueprint Medicines call participants 2 Introduction Kate Haviland , Chief Executive Officer Transaction Overview Mike Landsittel , Chief Financial Officer Q&A All PREPARED REMARKS Not for promotional use.
Slide 3: Forward-looking statements
Forward - looking statements 3 This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended . The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predi
Slide 4: Strategic, non-dilutive financing strengthens balance sheet and expands ability to bring precision therapy to broad patient populations
Strategic, non - dilutive financing strengthens balance sheet and expands ability to bring the promise of precision therapy to broad patient populations Validates confidence in commercial performance and market opportunity, particularly in systemic mastocytosis • Monetizes synthetic KIT (AYVAKIT, BL
Slide 5: Financing structure of up to $1.25B, with $575M funded at deal close
Financing structure of up to $1.25B, with $575M funded at deal close $175M Ex - US/Ex - China Royalty Monetization • Plus $165M in potential milestones $250M Synthetic Royalty Monetization • 9.75% subject to an annual cap of $900M in net sales • Initial cap at 1.45X investment $150M Senior Secured D
Slide 6: Thank you
(Sblueprint: Thank you